Can a common supplement shrink fatty liver in a rare diabetes?
NCT ID NCT07748130
First seen Aug 05, 2026 · Last updated Aug 06, 2026 · Updated 1 time
Summary
This trial tests whether taking coenzyme Q10 (CoQ10) for 12 weeks can reduce fat buildup in the liver of people with mitochondrial diabetes, a rare form of diabetes caused by mitochondrial dysfunction. Participants with the m.3243A>G mutation will take 300 mg of CoQ10 daily, and liver fat will be measured using a non-invasive ultrasound technique. The study also compares baseline characteristics among mitochondrial diabetes patients, type 1 diabetes patients, and healthy controls to better understand the link between mitochondrial defects and liver fat.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Coenzyme Q10 (CoQ10) supplement
- What this could lead to
- If CoQ10 reduces liver fat in mitochondrial diabetes, it could become a treatment for this rare condition and possibly for other fatty liver diseases.
- What could go wrong
- This is a small early-stage study with only 30 participants, so results may not apply broadly. CoQ10 may not significantly change liver fat, and the trial does not yet measure long-term outcomes.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MITOCHONDRIAL DIABETES are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
The 95th hospital of Putian
Putian, Fujian, 351100, China